Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

--------------------- Weekly 900 mg or less Weekly 1200 mg or 1500 mg ------------------------------------------------------------------------- Loading Dose 900 mg or less Loading Dose 1200 mg or more ------------------------------------------------------------------------- Daily Dose 100 mg or less Daily Dose 150 mg or more -------------------------------------------------------------------------

The dose schedules in the Phase 1 trials were weekly 100-800 mg or loading dose (LD) 300-1800 mg on Day 1 followed by 50-150 mg daily for Days 2-21 every 28 days or LD 400-900 mg & daily 50-100 mg continuously.

In the Phase 2 trials, doses were LD 900 mg Day 1 & 150 mg daily for days 2-21 every 28 days; LD 900 mg and 100 mg daily continuously; 50 mg daily continuously without a LD; and 900-1500 mg weekly. LD was reduced for cycle 2+ of the 28 day regimens.

Results

145 patients with sarcoma were entered on studies prior to December 31, 2006 and were assessed for CBR. Partial responses were seen, in one patient each, with chondrosarcoma, extra-skeletal myxoid chondrosarcoma, leiomyosarcoma and a desmoid tumor.

At lower doses with 52 patients fully evaluable for CBR, the CBR was 52% with 4 partial responses and 23 stable disease at >= 4 months.

At higher doses with 30 patients fully evaluable for CBR, the CBR was 53% with 16 stable disease at >= 4 months.

Toxicities were mainly gastrointestinal and/or fatigue. The percentage of patients with grade 0 nausea (N), vomiting (V), diarrhea (D) and fatigue (F) for lower dose perifosine (76 patients) was 46, 49, 38 and 55% respectively compared to 26, 32, 20 and 58 percent for higher dose perifosine (69 patients). The proportion of patients with grade 2+ N, V, D and F was 20, 13, 15 and 21% for lower dose perifosine and 49, 35, 42 and 25% for higher dose perifosine.

    Conclusions


    - Perifosin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:4/17/2015)... 17, 2015 Contego Medical, the first ... filter platform for angioplasty balloon and stent delivery ... Series B financing round led by Hatteras Venture ... focus on medical devices, biopharmaceuticals, diagnostics and related ... Mountain Group Partners, Lookout Capital and Medical Mutual. ...
(Date:4/17/2015)... NORTH CHICAGO, Ill. , April 17, 2015  AbbVie ... ABBV) today announced that it has extended the expiration of ... of common stock of Pharmacyclics, Inc. to 5 p.m., ... 2015. On April 17, 2015, AbbVie also ... Hart-Scott-Rodino Antitrust Improvements Act in order to provide the FTC ...
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
Breaking Medicine Technology:Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... April 17, 2015 In Defense of ... following statement: “On Wednesday April 15th, the European Parliament ... a resolution recognizing the Armenian Genocide, “paying tribute, on ... the one-and-a-half million innocent Armenian victims who perished in ... extols the EU for this timely and needed recognition ...
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. Steven ... platelet-rich plasma (PRP) and stem cell therapy. ... for its world-class care of injury-caused and chronic joint ... in many other physicians offering regenerative medicines. , ... pain management and rehabilitation. Dr. Meier and MOSM can ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... that computerized prescription could be used to avoid medical mistakes, ... to even more errors. ,It is known that adverse ... hospitals each year. One way hospitals are trying to cut ... But according to a new study, use of computerized systems ...
... antihypertensive strategies that use calcium channel blockers and ... with beta-blockers and diuretics. ,Hypertensive patients either ... without the ACE inhibitor perindopril or the beta-blocker ... ,The trial ran for five years, but it ...
... common form of brain cancer might fare better with a ... ,Based on findings of the study it was seen ... glioblastoma receive surgery to remove as much of the cancer ... study compared 573 patients with glioblastomas who were randomized to ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
... people it was found that men who drank six cups ... 12 to 18 years, while women who drank that amount ... their study revealed an unequivocal evidence for an inverse and ... other risk factors. However researchers say the reasons for ...
... Switzerland it was seen that the frequency of withholding ... a patient’s life varies greatly among European countries. The ... in diagnostics and treatment to save and sustain life. ... patient’s life, physicians may refrain from using all possible ...
Cached Medicine News:
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
... are packaged in easy open, single use, ... saturated with precisely the correct amount of ... saturated with a multi-purpose topical gel, for ... approved for venipuncture site preparation prior to ...
... Swabsticks are packaged in single-use ... Swabstick is saturated with precisely ... Each package is terminally sterilized, ... for the patient. Swabstick provides ...
Medicine Products: